Monash University will license technology related to inhaled oxytocin for the treatment of postpartum hemorrhage to to GSK, the university and GSK have announced. Monash and GSK will collaborate on development through early clinical trials, including product optimization and manufacturing process development.
Development of the dry powder formulation will be funded by a total of $16.6 million from GSK, the McCall MacBain Foundation, Grand Challenges Canada, and Planet Wheeler Foundation.
GSK VP for East Africa Allan Pamba commented, “In GSK’s Maternal and Neonatal Health Unit, R&D, we are constantly challenging ourselves to find new interventions that improve the life chances of mothers and their newborns. Collaborating with others is fundamental to these efforts and we are delighted to partner with Monash. By combining their technical expertise with our experience in drug development and respiratory know-how, we have the potential to give new mothers a fighting chance.”
Monash Institute of Pharmaceutical Sciences (MIPS) Director Bill Charman said, “Thanks to the generosity and support of our partners, turning our research into a new medicine that has the potential to save lives globally is now within our grasp.”
Read the GSK and Monash University press release.
